Isolation of nontuberculous, non-avium mycobacteria from patients infected with human immunodeficiency virus.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Isolation of nontuberculous, non-avium mycobacteria from patients infected with human immunodeficiency virus.

Clin Infect Dis. 1995 Jan;20(1):73-6. Unique Identifier : AIDSLINE MED/95244756
Raszka WV Jr; Skillman LP; McEvoy PL; Robb ML; Department of Pediatrics, William Beaumont Army Medical Center,; El Paso, Texas 79920.

Abstract: Mycobacterium avium serovars account for 97% of typeable M. avium complex (MAC) organisms causing infection in patients with AIDS. We reviewed 216 consecutive cultures that yielded nontuberculous mycobacteria (NTM) from 212 patients. Only the first isolate of each species of NTM recovered from each patient was analyzed in the study. Among the 92 patients infected with the human immunodeficiency virus, 96 NTM organisms were identified; M. avium was recovered from 50 (77%) of the 65 NTM-positive cultures of blood or bone marrow, while Mycobacterium intracellular and other non-avium NTM accounted for 18% and 5% of the isolates, respectively. Little difference in the susceptibility of isolates to antibiotics was noted between HIV-positive and HIV-negative patients or between M. avium and M. intracellulare. These data demonstrate that HIV-positive patients develop disseminated disease with NTM other than M. avium more frequently than has been previously reported and that these patients do not appear to be infected with NTM that are more resistant to antimicrobial agents than are NTM isolated from HIV-negative patients.

Keywords: Adolescence Adult Aged Aged, 80 and over AIDS-Related Opportunistic Infections/DRUG THERAPY/*MICROBIOLOGY Child Child, Preschool Drug Resistance, Microbial Female Human Infant Male Middle Age Mycobacterium/CLASSIFICATION/DRUG EFFECTS/ISOLATION & PURIF Mycobacterium avium Complex/CLASSIFICATION/DRUG EFFECTS/ISOLATION & PURIF Mycobacterium avium-intracellulare Infection/COMPLICATIONS/DRUG THERAPY/MICROBIOLOGY Mycobacterium Infections/*COMPLICATIONS/DRUG THERAPY/ *MICROBIOLOGY Support, U.S. Gov't, Non-P.H.S. JOURNAL ARTICLE
950830
M9580953

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .